Ludwig Institute for Cancer Research Limited

Bernard Lethe

Thierry R Boon-Falleur

Aline Van Pel

Vincent Brichard

Etienne DePlaen

Pierre G Coulie

Thomas Wolfel

Pierre Van Der Bruggen

Etienne De Plaen

Charles De Smet

Jean-Christophe Renauld

Sophie Lucas

Christophe Lurquin

Francis Brasseur

Daniele Godelaine

Charles DeSmet

Jean-Christope Renauld

Benoit Van Den Eynde

Jacques Van Snick

Pascal Chaux

Vincent Stroobant

Beatrice Gaugler

Patrick Chomez

Kris Thielemans

Erwin Schultz

Thomas W&ouml;lfel

Jean-Pierre Szikora

Pierre Van Der Bruggan

Carlo Heirman

Jurgen Corthals

Thierry Boon-Fallaur

Francis Basseur

P Weynants

M Marchand

Marie Marchand

Patrick Weynants

The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.

Lage-1 tumor associated nucleic acids

The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.

The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4 T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.

Mage-A3 peptides presented by HLA class molecules

The invention relates to complexes of human leukocyte antigen molecules and tyrosinase derived peptides SEQ ID NO: 2, on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.

METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HUMAN LEUKOCYTE ANTIGEN TYROSINASE DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS

The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.

Isolated tyrosinase derived peptides and uses thereof

A method for determining lung adenocarcinomas is described. The method involves assaying for expression of a gene coding for at least one of tumor rejection antigen precursors MAGE-1, 2 and 3, or their expression product.

Method for determining lung adenocarcinomas by assaying for one or more

Isolated, tyrosinase derived peptides and uses thereof

The invention relates to nucleic acid molecules which are useful in determining expression of the family of molecules known as the MAGE tumor rejection antigen precursors. These nucleic acid are molecules useful as diagnostic aids for determining whether or not an individual has cancer. Methods using these molecules are also described.

Isolated nucleic acid molecules useful in determining expression of a

A method for determining head and neck squamous cell carcinomas, bladder tumors and prostate carcinomas is described. The method involves assaying for expression of the gene coding for tumor rejection antigen precursor MAGE-3, or its expression product. Various assays, and kits useful for these assays, are described.

Method for determining head and neck squamous cell carcinomas, prostate

The invention relates to the identification of complexes of human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase-derived peptide having the amino acid sequence Met Leu Leu Ala Val Leu Tyr Cys Leu Leu. The invention further relates to the detection of these complexes on the surface of abnormal cells and, in particular, on the surface of melanoma cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.

Method for detecting complexes containing human leukocyte antigen A2

Growing community of inventors

Brussels, Belgium

Bernard Lethe